We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Possible Bio-Marker for Type 2 Diabetes Identified

By Biotechdaily staff writers
Posted on 12 Jul 2006
Researchers have found that retinol-binding protein 4 (RBP4), a molecule that transports vitamin A in the blood, might be an effective marker for predicting the likelihood of developing non-insulin-dependent diabetes (type 2) diabetes.

Type 2 diabetes, also called adult-onset diabetes, results from the inability of the cells in the body to respond to insulin. More...
About 90% of diabetics have this form, which is more prevalent in non-whites and usually occurs after age 40. Although the cause is not completely understood, there is a genetic factor and 90% of those affected are obese.

Investigators at Harvard Medical School (Boston, MA, USA) exploited previous findings that RBP4, a protein secreted from adipose tissue, was linked to insulin resistance in mice. In the current study they measured serum RBP4 levels, insulin resistance, and components of the metabolic syndrome in three groups of subjects (from the United States, Sweden, and Germany). Individuals in one set of subjects were obese, demonstrated impaired glucose tolerance, or were ill with type 2 diabetes. Individuals in a second group had normal body weight and normal blood glucose, but had a strong family history of type 2 diabetes.

Results published in the June 15, 2006, issue of The New England Journal of Medicine, revealed that serum RBP4 levels correlated with the magnitude of insulin resistance in subjects with obesity, impaired glucose tolerance, or type 2 diabetes and in non-obese, non-diabetic subjects with a strong family history of type 2 diabetes. Elevated serum RBP4 was associated with components of the metabolic syndrome, including increased body-mass index, waist-to-hip ratio, serum triglyceride levels, systolic blood pressure, and decreased high-density lipoprotein cholesterol levels.

Some patients were assigned an exercise regimen to lower their weight and degree of insulin resistance. Only those showing an improvement in insulin resistance experienced a reduction in serum RBP4 levels.

"Collectively, these findings tell us that RBP4 is a useful marker for therapeutic improvement and that this protein could play a causal role in insulin resistance in humans, just as our lab previously showed in mice,” said senior author Dr. Barbara Kahn, professor of endocrinology at Harvard Medical School. "Furthermore, because RBP4 levels consistently corresponded with insulin resistance--even among lean subjects whose genetic risk for the development of diabetes might otherwise be overlooked--this protein could be an important marker for type 2 diabetes among the general population. Being able to determine diabetes risk well before the onset of symptoms could provide an important opportunity for patients to take preventive measures.”



Related Links:
Harvard Medical School

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.